1. Ierapetritou M, Muzzio F, Reklaitis G. Perspectives on the continuous manufacturing of powder-based pharmaceutical processes. AICHE J. 2016;62(6):1846–62.
https://doi.org/10.1002/aic.15210
.
2. Chatterjee S. FDA perspective on continuous manufacturing—IFPAC Annual Meeting in Baltimore. January 2012.
https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM341197.pdf
. Accessed 12.06.2017.
3. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Office of Regulatory Affairs (ORA). Guidance for industry: PAT—a framework for innovative pharmaceutical development, manufacturing and quality assurance (Pharmaceutical cGMPs). 2004.
https://www.fda.gov/downloads/drugs/guidances/ucm070305.pdf
. Accessed 12.06.2017.
4. Allison G, Cain YT, Cooney C, Garcia T, Bizjak TG, Holte O, et al. Regulatory and quality considerations for continuous manufacturing May 20–21, 2014 Continuous Manufacturing Symposium. J Pharm Sci. 2015;104(3):803–12.
https://doi.org/10.1002/jps.24324
.
5. The Brookings Institution. Promoting continuous manufacturing in the pharmaceutical sector—discussion guide. In: Center for Health Policy at Brookings. The Brookings Institution, 1775 Massachusetts Ave., Washington, DC. 2015.
https://www.brookings.edu/wp-content/uploads/2015/10/Continuous-manufacturing-discussion-guide.pdf
. Accessed 18.07.2017.